Recently the FDA gave a full approval to what many scientists and doctors believe, is the first drug to show an ability to slow down the development of Alzheimer’s disease.
While patients’ advocates are celebrating, criticizers see it as the unsuccessful triumph of an imperfect theory of the disease’s cause and guessed the rollout of the drug will worsen racial differences in elder care. Break through in Alzheimer’s cure may not be for black patients.
Last month the FDA advisory panel voted 6-0 to support FDA approval of Iecanemab, from the Japanese pharmaceutical company Eisai. Around 1,800 early-stage Alzheimer’s patients were involved in a clinical trial. Those who got biweekly infusion, the drug reduced development of the disease compared with those given placebo.
But the drug didn’t reverse Alzheimer’s symptoms, for months or years it will carefully monitor patients, including a many brains scan. Individuals receiving Iecanemab, with the brand name Leqembi, are likely to double compared to placebo recipients, to suffer swelling of the brain or hemorrhaging in major trials. The drug striping away amyloid proteins are considered minor but causing three deaths due to the drug.
With the FDA approval of Iecanemab, Eisai is set to encourage to the primary care physicians who treat most dementia patients and criticizers are speaking out.
Libby Holman, Eisai spokesperson informs, though varied populations worked to register by the company, a contrast level existed between racial and ethnic groups. If those do not have elevated amyloid then they do not have Alzheimer’s disease.
In many studies blacks are up to twice as likely as whites to have Alzheimer’s, yet they show same levels of amyloid. No one is exactly sure why the reason is but the hypothesis is that having several simultaneous health conditions and being exposed to environmental stressors put Blacks as a group at higher risk.
However, at later stages minorities and blacks tend to be detected, excluding them from the use of Iecanemab, designed and proved to overcome early stage of Alzheimer’s.
At the early stage of the disease, the drug has to be used. It’s well recognized that marginalized communities and people don’t get entrée to diagnostic services as do more privileged populations, since our medical care is two-tiered.
Joanne Pike, the CEO of the Alzheimer’s Association, noted that patients on Iecanemab declined five months more slowly in their first 18 months on the drug, on average.
From the Alzheimer’s Association, Perry received research funding, questions its strong support for the drug but isn’t surprised. Given the group’s promise to its members and supporters to help find a cure for the disease.
